Colorado to expand coverage for Hep C patients, but some still won’t get the expensive drug

Is That an MS Symptom? Or Am I Just Sore and Tired?
September 9, 2016
Cancer Drug Prices Still Rapidly Rising
September 9, 2016
Show all

Colorado to expand coverage for Hep C patients, but some still won’t get the expensive drug

Some states are increasing access to hepatitis C medications.

Colorado will increase access to a life-saving, expensive hepatitis C drug, covering needy patients in earlier stages of liver disease than were previously considered, the state Medicaid department said Thursday.

The decision comes after criticism from the ACLU Colorado and Denver Health Medical Center and a recommendation from the state drug review board, which provides guidance on drug coverage for the state insurance program for needy Coloradans.

The state has paid for the 12-week drug treatment with a 90 percent cure rate only for patients who were in the final two stages of liver disease. Under the new policy, Medicaid patients can receive the drug if their liver damage has advanced to the second out of five stages — zero meaning no liver damage and four diagnosed as cirrhosis.

The policy also expands coverage to women who plan to become pregnant within the next year, regardless of the stage of their liver scarring. And it loosens a previous restriction barring anyone who used alcohol or illegal drugs within the last six months. Now people with a history of chronic substance abuse will have to enroll in drug treatment counseling at least one month before receiving the hepatitis C regime.

Read Full Article: Colorado to expand coverage for Hep C patients, but some still won’t get the expensive drug – 7NEWS Denver TheDenverChannel.com

Read Full Article: Colorado to expand coverage for Hep C patients, but some still won’t get the expensive drug – 7NEWS Denver TheDenverChannel.com

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.